Pandemic Cancer Incidence Observance Shows Further Recovery Still Needed
A study observed differences between expected and observed cancer incidence in 2020 and 2021 to evaluate the pandemic’s disruption of cancer detection.
Related Articles
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation
This randomized clinical trial evaluates the efficacy of sharing follow-up care between the specialty center and a local oncology practice after allogeneic hematopoietic cell transplantation.
2025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
Combination induces durable responses in advanced multiple myeloma
The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.“Combination…
Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma
Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.
Program: Tuesday, February 25
tuesday, february 25 *-Short talk from proffered abstract CONTINENTAL BREAKFAST 7-8 a.m. Major Symposia 4-5 8-9:30 a.m. Major Symposium 4: Neoadjuvant Immunotherapy Session Chair: Christian…
Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC
Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.
Managing Intermediate-Risk Myelofibrosis With Ruxolitinib
During a Case-Based Roundtable® event, Andrew Kuykendall, MD, discussed treatment for a 68-year-old patient with intermediate-1 risk myelofibrosis and mild anemia.
IMM-1-104 Regimens Yield Promising Activity in Pancreatic Cancer
Investigators of a phase 2a trial plan to include additional combination arms assessing treatment with IMM-1-104 across different patient populations.
Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome
Duvelisib plus venetoclax was active in relapsed/refractory CLL and Richter syndrome with high-risk, TP53-aberrant disease after BTK inhibition.
ICR welcomes NICE recommendation of olaparib for advanced breast cancer
ICR welcomes NICE recommendation of olaparib for advanced breast cancer
